Yvonne Flores-Medina

Dr. Yvonne Flores-Medina

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2020 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
SASamantha Alvarez-Herrera
Samantha Alvarez-Herrera
RERaúl Escamilla
Raúl Escamilla
OMOscar Medina-Contreras
Oscar Medina-Contreras
RSRicardo Saracco
Ricardo Saracco
YFYvonne Flores-Medina
Yvonne Flores-Medina
Lenin PavónLenin Pavón
Lenin Pavón
Atypical antipsychotics (AAP) or second-generation antipsychotics are the clinical option for schizophrenia treatment during acute psychoses, but they are also indicated for maintenance during lifetime, even though they are being used for other psychiatric conditions in clinical practice such as affective disorders and autism spectrum disorder, among others. These drugs are differentiated from typical antipsychotics based on their clinical profile and are a better choice because they cause fewer side effects regarding extrapyramidal symptoms (EPS). Even though they provide clear therapeutic benefits, AAP induce peripheral effects that trigger phenotypic, functional, and systemic changes outside the Central Nervous System (CNS). Metabolic disease is frequently associated with AAP and significantly impacts the patient's quality of life. However, other peripheral changes of clinical relevance are present during AAP treatment, such as alterations in the immune and endocrine systems as well as the intestinal microbiome. These less studied alterations also have a significant impact in the patient's health status. This manuscript aims to revise the peripheral immunological, endocrine, and intestinal microbiome changes induced by AAP consumption recommended in the clinical guidelines for schizophrenia and other psychiatric disorders.

28 January 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Priscila Samantha Alvarez-HerreraPriscila Samantha Alvarez-Herrera
Priscila Samantha Alvarez-Herrera
MVMauricio Rosel Vales
Mauricio Rosel Vales
Gilberto Pérez--SánchezGilberto Pérez--Sánchez
Gilberto Pérez--Sánchez
Enrique Becerril VillanuevaEnrique Becerril Villanueva
Enrique Becerril Villanueva
YFYvonne Flores-Medina
Yvonne Flores-Medina
Lenin PavónLenin Pavón
Lenin Pavón
Dopamine and serotonin receptors and transporters play an essential role in the pathophysiology of schizophrenia; changes in their expression have been reported in neurons and leukocytes. Each antipsychotic induces a unique pattern in leukocyte function and phenotype. However, the use of polytherapy to treat schizophrenia makes it challenging to determine the specific effects of risperidone on peripheral blood mononuclear cells (PBMCs). The aim of this study was to evaluate the changes in the expression of D3, D5, DAT, 5-HT2A, and SERT in PBMCs from healthy volunteers (HV), drug-naive patients with schizophrenia (PWS), drug-free PWS, and PWS treated with risperidone for up to 40 weeks using quantitative PCR. Our study revealed elevated mRNA levels of D3, DAT, 5-HT2A, and SERT in unmedicated PWS. Treatment with risperidone led to a reduction only in the expression of 5-HT2A and SERT. Furthermore, we observed a moderate correlation between 5-HT2A expression and the positive and negative syndrome scale (PANSS), as well as SERT expression and PANSS scale. We also found a moderate correlation between 5-HT2A and SERT expression and the positive subscale. The duration of risperidone consumption had a significant negative correlation with the expression of 5-HT2A and SERT. Our study introduces the measurement of 5-HT2A and SERT expression in PBMCs as a useful parameter for assessing the response to risperidone in PWS.

1 February 2014 in Brain and Cognition
Verified
Journal Article
Closed access
YFYvonne Flores-Medina
Yvonne Flores-Medina
MOMireya Alejandra Chávez Oliveros
Mireya Alejandra Chávez Oliveros
LMLuis D Medina
Luis D Medina
YRYaneth Rodríguez-Agudelo
Yaneth Rodríguez-Agudelo
RSRodolfo Solís-Vivanco
Rodolfo Solís-Vivanco

25 May 2024 in Virtual Reality
Verified
Journal Article
Open access
PDF file
DPD. A. Pérez-Ferrara
D. A. Pérez-Ferrara
YFYvonne Flores-Medina
Yvonne Flores-Medina
ELE. Landa-Ramírez
E. Landa-Ramírez
DGD. J. González-Sánchez
D. J. González-Sánchez
JLJ. A. Luna-Padilla
J. A. Luna-Padilla
AMA. Mondragón-Maya
A. Mondragón-Maya
To date, many interventions for social cognition have been developed. Nevertheless, the use of social cognition training with virtual reality (SCT-VR) in schizophrenia is a recent field of study. Therefore, a scoping review is a suitable method to examine the extent of existing literature, the characteristics of the studies, and the SCT-VR. Additionally, it allows us to summarize findings from a heterogeneous body of knowledge and identify gaps in the literature favoring the planning and conduct of future research. The aim of this review was to explore and describe the characteristics of SCT-VR in schizophrenia. The searched databases were MEDLINE, PsycInfo, Web of Science, and CINAHL. This scoping review considered experimental, quasi-experimental, analytical observational and descriptive observational study designs. The full text of selected citations was assessed by two independent reviewers. Data were extracted from papers included in the scoping review by two independent reviewers. We identified 1,407 records. A total of twelve studies were included for analyses. Study designs were variable, most research was proof-of-concept or pilot studies. Most SCT-VR were immersive and targeted interventions. Number of sessions ranged from 9 to 16, and the duration of each session ranged from 45 to 120 min. Some studies reported a significant improvement in emotion recognition and/or theory of mind. However, SCT-VR is a recent research field in which the heterogeneity in methodological approaches is evident and has prevented the reaching of robust conclusions. Preliminary evidence has shown that SCT-VR could represent a feasible and promising approach for improving SC deficits in schizophrenia.

9 July 2022 in Heliyon
Verified
Journal Article
Open access
YFYvonne Flores-Medina
Yvonne Flores-Medina
YRYaneth Rodríguez-Agudelo
Yaneth Rodríguez-Agudelo
JBJorge Bernal-Hernández
Jorge Bernal-Hernández
CCCarlos S. Cruz-Fuentes
Carlos S. Cruz-Fuentes
To evaluate the putative detrimental effect of Major Depressive Disorder (MDD) on the cognitive impairment associated with Alcohol Dependence (AD), we contrasted the neuropsychological profile and behavioral responses of AD subjects, MDD individuals, and in those with a co-occurring AD-MDD diagnosis (DD). Patients and healthy subjects completed a comprehensive neuropsychological battery and were recorded for P200, P300, and N450 event-related potentials during memory and Stroop tasks. AD subjects exhibited a generalized detrimental neuropsychological performance; in contrast, in MDD individuals, impairment was limited to discrete domains. Notably, the deficits were distinctive in DD cases. A P200 increased amplitude in MDD, a decrease in P300 amplitude in AD, and increased latency of P300 in DD patients were the overt electrophysiological abnormalities identified. Dual patients also exhibited a distinct pattern of behavioral responses, particularly apparent during high-demand cognitive tasks. Specific ERP adjustments were associated with the short-term fluoxetine treatment in DD and MDD subjects; the SSRI also improved altered baseline performance in learning and cognitive flexibility in DD subjects. In conclusion, the neuropsychological and behavioral alterations detected in the co-occurrence of AD-MDD did not seem to be merely the sum of the negative contributions of the independent disorders.

29 August 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
YFYvonne Flores-Medina
Yvonne Flores-Medina
RBRegina Avila Bretherton
Regina Avila Bretherton
JESUS RAMIREZ-BERMUDEZJESUS RAMIREZ-BERMUDEZ
JESUS RAMIREZ-BERMUDEZ
RSRICARDO ARTURO SARACCO-ALVAREZ
RICARDO ARTURO SARACCO-ALVAREZ
MFMónica Flores-Ramos
Mónica Flores-Ramos
A two-factor account has been proposed as an explanatory model for the formation and maintenance of delusions. The first factor refers to a neurocognitive process leading to a significant change in subjective experience; the second factor has been regarded as a failure in hypothesis evaluation characterized by an impairment in metacognitive ability. This study was focused on the assessment of metacognition in patients with schizophrenia. The aims of the study were to measure the overconfidence in metacognitive judgments through the prediction of word list recall and to analyze the correlation between basic neurocognition (memory and executive function) and metacognition through a metamemory test and the severity of psychotic symptoms. Method: Fifty-one participants with a diagnosis of schizophrenia were evaluated. The Positive and Negative Syndrome Scale (PANSS) was used to assess the severity of psychiatric symptoms, and the subtest of metamemory included in the Executive Functions and Frontal Lobe-2 battery (BANFE-2) was used to evaluate overconfidence and underestimation errors, intrusion and perseverative response, total volume of recall, and Brief Functioning Assessment Scale (FAST) for social functioning. Results: The strongest correlation is observed between overconfidence errors and the positive factor of the PANSS (r = 0.774, p < 0.001). For the enter model in the multiple linear regression (r = 0.78, r2 = 0.61; F = 24.57, p < 0.001), the only significant predictor was overconfidence errors. Conclusion: Our results highlight the relevance of a metacognitive bias of overconfidence, strongly correlated with psychotic symptoms, and support the hypothesis that metacognitive defects contribute to the failure to reject contradictory evidence. From our perspective, these findings align with current mechanistic models of schizophrenia that focus on the role of the prefrontal cortex.